drugset / Trial / NCT01536015

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

NCT01536015

Phase 3 Terminated 25 enrolled UCB Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.

Timeline

Start
2012-01
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 8 mg Other

Indications